New Rheumatoid Arthritis Treatments for 'Old' Patients: Results of a Systematic Review.

ABSTRACT:

Introduction

In the last 20 years, biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) have become available for treating rheumatoid arthritis (RA), and a treat-to-target strategy has been introduced. We hypothesise that these advances should have resulted in changes to the characteristics of patients with RA participating in clinical trials of the newest therapies. This study determined whether the baseline characteristics of patients with RA enrolled in clinical trials have changed in the past decade versus patients participating in earlier RA studies.

Methods

This secondary analysis was based on randomised controlled trials (RCTs) identified in a systematic literature review. Baseline characteristics of patients with RA with inadequate response

SUBMITTER: Caporali R 

PROVIDER: S-EPMC7444401 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature